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ABSTRACT
Background: Matrix metalloproteinases (MMPs) have been reported to play crucial roles in the migration of
inflammatory cells through basement membrane components. To confirm the role of mast cells as a source of
MMPs, we investigated the production of MMP and its pathway in human cultured mast cells (HCMC). We also
investigated the production of tissue inhibitors of metalloproteinase (TIMPs).
Methods: HCMC was stimulated with phorbor 12-miristate 13-acetate (PMA) andor calcium ionophore
A23187 (A23187), and the resulting MMP production was evaluated by gelatin zymography and western blot-
ting. Expression of MMP and TIMP mRNA was also examined. Granulocyte macrophage-colony stimulating
factor (GM-CSF) was measured by ELISA and activation of extracellular signal-regulated kinase (ERK) was
evaluated by western blotting.
Results: We detected the de novo synthesis of MMP-9 in HCMC after stimulation with PMA and found that the
synthesis was mediated through protein kinase C―mitogen activated protein kinase kinase (MEK)―ERK path-
way. The MMP-9 production induced by PMA was suppressed by simultaneous treatment with A23187,
whereas GM-CSF production was potentiated. We also detected the expression of mRNA for membrane-type 1
(MT1)-MMP, TIMP-1 and TIMP-2 after stimulation with PMA. Glucocorticoids and flavonoids inhibited MMP-9
production, and TIMPs and MMP inhibitors inhibited the gelatinolytic activity of mast cell-derived MMP-9. Fur-
thermore, phenylmethylsulfonyl fluoride, a protease inhibitor, inhibited the conversion from proMMP-9 to active
MMP-9.
Conclusions: These results suggest that the human mast cell is a leading member of MMP production, and
the production, activation and activity are controllable by pharmacological agents.
KEY WORDS
human cultured mast cells, matrix metalloproteinase-9, membrane type matrix metalloproteinase, tissue inhibi-
tor of metalloproteinase-1, tissue inhibitor of metalloproteinase-2
INTRODUCTION
Matrix metalloproteinases (MMP) are a family of
zinc- and calcium-dependent endopeptidases capable
of proteolytically degrading many of the components
of the extracellular matrix.1 MMP are produced by
not only structural cells such as fibroblasts, endothe-
lial cells and epithelial cells,2 but also by inflamma-
tory cells such as macrophages,3 lymphocytes,4 neu-
trophils5 and eosinophils.6,7 MMP are secreted as la-
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tent forms followed by proteolytic processing to ac-
tive forms , and involved in physiologic processes
such as development, angiogenesis and wound heal-
ing, and in pathologic conditions such as tumor inva-
sion and inflammation.2,8 The proteolytic activation
of latent forms and enzymatic activities of active
forms of MMP are inhibited by endogeneous inhibi-
tors , tissue inhibitors of metalloproteinase (TIMP)
that form a 1:1 complex with MMP.9 The balance be-
tween the levels of MMP and TIMP is thought to be a
critical factor in regulating the breakdown of connec-
tive tissues by MMP, which is the case in pulmonary
emphysema.10 While the majority of the MMP are
secreted as soluble enzymes into the extracellular mi-
lieu, a subset of MMP has been identified in recent
years to contain additional sequences downstream of
the hemopexin-like domain capable of anchoring on
plasma membrane . 11,12 Named after the putative
transmembrane domains as membrane-type matrix
metalloproteinase 1 to 5 (MT1-, MT2-, MT3-, MT4-
and MT5-MMPs) , these enzymes have been pro-
posed to be the master switches of extracellular ma-
trix turnover based on the purported ability of MT-
MMP to activate other MMP.13,14
MMP has been recognized because of its participa-
tion in allergic inflammatory diseases such as bron-
chial asthma, especially in remodeling and fibrosis. 15-17
These enzymes make it possible for inflammatory
cells to infiltrate inflammatory sites . Especially,
eosinophil transmigration is well explained with re-
gard to the role of MMP-9. 18 The production of
MMP from inflammatory cells such as eosinophils,6,7
neutrophils5 and macrophages3 has been well inves-
tigated in vivo and in vitro, although the production
of MMP from mast cells is less understood. As for
mast cells , several investigators have reported the
production of MMP from some types of mast cells
(mouse mast cells, dog mastocytoma cells and hu-
man mast cells).19-22 However, the production path-
way of MMP from mast cells and its regulation have
not been investigated yet. In this report, therefore,
we investigated the MMP production and its pathway
using human cultured mast cells (HCMC)．
METHODS
AGENTS
Actinomycin D ( Act . D ) , cycloheximide ( CHX ) ,
aminophenylmercuric acetate (APMA), phenylmeth-
ylsulfonyl fluoride (PMSF), and staurosporine were
purchased from Sigma (St. Louis, MO, USA). U0126
and PD9805923 were obtained from Promega (Madi-
son, WI, USA) and Calbiochem (La Jolla, CA, USA),
respectively. Bisindolylmaleimide II (BIS II ; Alexis
Co., San Diego, CA, USA), prednisolone phosphate
(Banyu Co. , Tokyo, Japan) , dexamethasone phos-
phate (Takeda Chemical Industries, LTD., Osaka, Ja-
pan ) , luteolin (Sigma) , baicalein ( Extrasynthese ,
Genay, France), quercetin (Extrasynthese), TIMP-1
and TIMP-2 (Fuji Chemical Industries, LTD, Toyama,
Japan) were obtained from each respective company.
AG-3340,24 marimastat,24 CGS27023A25 and Ro32−
3555 26 were synthesized . Concentrations of the
agents employed were decided according to our pre-
liminary experiments．
HUMAN MAST CELL CULTURE
HCMC were obtained by culturing human umbilical
cord blood cells using a method described previ-
ously. 27 Briefly , heparinized umbilical cord blood
was donated from mothers with informed consent
and mononuclear cells (MNC) were separated from
the blood by lymphocyte separation medium (ICN
Biomedicals Inc., Aurora, OH, USA) gradient. CD34+
cells were purified from the MNC fraction by using a
CD34+ progenitor cell isolation kit (Miltenyi Biotec,
Bergisch Gladbach , Germany ) and magnetic cell
sorting system (MACS; Miltenyi Biotec). Purified CD
34+ cells were cultured in an α-minimum essential
medium (GIBCO-RBL Laboratories , Gland Island ,
NY, USA) containing 15% fetal bovine serum (Filtron
Pty Ltd., Brooklyn, Australia) in the presence of 80
ngml human recombinant stem cell factor (SCF ;
Kirin Brewery, Maebashi, Japan) and 50 ngml hu-
man recombinant interleukin-6 (Kirin ) . Cells were
harvested weekly and resuspended in a fresh media.
The purity of mast cells was determined by toluidine
blue and May-Gruenwald and Giemsa staining. Im-
munoperoxidase staining for tryptase and chymase
was performed by the method previously estab-
lished.28 HCMC employed in the present study con-
sisted of a more than 15 week-old culture with >99%
purity . The HCMC were almost 100% positive for
tryptase and 14% positive for chymase．
DETECTION OF EXTRACELLULAR-
REGULATED KINASE (ERK) AND MMP-9
BY WESTERN BLOTTING
HCMC were stimulated with phorbor 12-myristate 13-
acetate (PMA) or anti-IgE for indicated periods as re-
ported previously . 29 To stimulate HCMC IgE-
dependently, HCMC were incubated in the presence
of 1 μgml human myeloma IgE (Chemicon Int. Inc.,
Temecula, CA, USA) at 37℃ overnight and then chal-
lenged with 4 μgml anti-human IgE (DAKO, Clos-
trup, Denmark). For the detection of ERK, stimulated
cells (1×105 cellslane) were lysed with ice-cold lysis
buffer (50 mM Tris-HCl, pH 7.5; 0.15 M NaCl , 1%
IGEPAL CA-630, 10 μgml aprotinin, 10 μgml leu-
peptin, 1 mM EDTA and 1mM Na3VO4). For the de-
tection of MMP-9, HCMC (5×105 cellsml ) were
stimulated for indicated periods, and then the super-
natants were separated. Analysis of samples by SDS-
PAGE and transfer to PVDF membrane (PVDF-Plus,
pore size =0.45 micron ; Micron Separations , Inc . ,
Westboro, MA, USA) were performed as described
68 Allergology International Vol 55, No1, 2006 www.jsaweb.jp
Kimata M et al.
elsewhere.30 ERK and MMP-9 were detected with
the antibodies against phosphorylated forms of ERK
(Phospho-p4442 MAP Kinase antibody; New Eng-
land Biolabs, Inc. , Bevery, MO, USA) and MMP-9
(Fuji Chemical Ind. , LTD), respectively . The anti-
MMP-9 antibodies detected both proMMP-9 and ac-
tive MMP-9. Horseradish peroxidase-conjugated anti-
bodies against rabbit IgG (for ERK; Promega, Madi-
son , WI , USA ) and mouse IgG ( for MMP-9 ;
Promega) were used as secondary antibodies . Fi-
nally, the proteins were visualized by the ECL-plus
system (Amersham)．
DETECTION OF MMP PRODUCTION BY
GELATIN ZYMOGRAPHY
HCMC at a concentration of 5×105 cellsml were in-
cubated with PMA in serum-free medium for indi-
cated periods and culture supernatants were har-
vested . Gelatin zymography was performed as de-
scribed previously with some modifications. 31 The
culture supernatant was electrophoresed in 10% poly-
acrylamide gels containing 1 mgml gelatin in the
presence of SDS under non-reducing conditions. Gels
were then washed three times in 50 mM Tris-HCl, pH
7.5, containing 2.5% Triton X-100, 10 mM CaCl2 and 1
mM ZnCl2, and further incubated in Triton X-100
buffer at 37℃ for 24 hr . Following incubation, the
gels were stained with Coomassie brilliant blue R
250. Destaining visualized clear zones of lysis against
a blue background indicated gelatinase activity.
When the effects of drugs on MMP production were
examined, drugs were added to HCMC suspension
10 min before PMA stimulation．
EFFECTS OF TIMPS AND MMP INHIBI-
TORS ON MMP-9 ACTIVITY
Effects of TIMPs and MMP inhibitors on MMP-9 ac-
tivity were examined by gelatin zymography. HCMC
were incubated with PMA at a concentration of 10
nM for 48 hr, and the supernatant was separated and
used as a source of MMP-9. The supernatant was
electrophoresed in gelatin containing gels , and the
gels were further incubated for 24 hr in the presence
of TIMPs and MMP inhibitors. EDTA , which
chelates calcium and zinc ions, was tested as a posi-
tive control．
GM-CSF PRODUCTION
HCMC were resuspended at 5×105 cellsml in fresh
culture media and challenged with PMA and calcium
ionophore A23187 (A23187; Sigma) for 6 hr. GM-CSF
in the supernatant was quantified using a commercial
ELISA kit (R&D Systems, Inc. , Minneapolis, MN,
USA).
ISOLATION OF RNA AND REVERSE
TRANSCRIPTASE-POLYMERASE CHAIN
REACTION (RT-PCR)
Total cellular RNA was isolated from stimulated
HCMC using Isogen (Nippon gene Co, Tokyo, Ja-
pan). The first-strand cDNA was synthesized from 1
μg of total RNA using the superscript preamplifica-
tion system (GIBCO-RBL Laboratories) according to
the manufacture’s instruction. PCR was performed as
follows: 94℃，90 seconds of denaturing; 62℃，90 sec-
onds of annealing; and 72℃，90 seconds of extension,
for 30 cycles (β-actin) or 32 cycles (others). Primers
used were as follows:β-actin, sens: 5’-CAAGAGATGG
CCACGGCTGCT-3’, antisense: 5’-TCCTTCTGCATC
CTGTCGGCA-3’; MMP-9, sens: 5’-GTGCTGGGCTG
CTGCTTTGCTG-3’, antisense: 5’-GTCGCCCTCAAA
GGTTTGGAAT-3’; MT1-MMP, sens: 5’-TCGGCCCA
AAGCAGCAGCTTC-3’, antisense: 5’-CTTCATGGTG
TCTGCATCAGC-3’; TIMP-1, sens: 5’-TGCACCTGTG
TCCCACCCCACCCACAGACG-3’, antisense: 5’-GGC
TATCTGGGACCGCAGGGACTGCCAGGT-3’; TIMP-
2, sens: 5’-CAGCCGAGCAGCCACATCG-3’, antisens
e: 5’-TGAGGCTGTTGTCATACTTCTC-3’.PCR prod-
ucts were analyzed by agarose gel electrophoresis．
RESULTS
MMP PRODUCTION FROM HCMC
HCMC were stimulated with 10 nM PMA for 12―96
hours and gelatinolytic activity in the supernatant was
examined by gelatin zymography. As shown in Fig-
ure 1A, 3 gelatinolytic bands were detected. Accord-
ing to the position, upper bands and middle bands
were considered to be proMMP-9 and active MMP-9,
respectively. The band for proMMP-9 was observed
from 12 hours after the stimulation and increased up
to 96 hours, and that for active MMP-9 was detected
from 24 hours after the stimulation. The lower dim
bands only detected after 96 hours seemed to be
MMP-2 according to the report by Kanbe et al.19
Because it was considered that gelatin zymography
might be less quantitative , we carried out western
blot analysis to confirm the MMP-9 production. We
employed monoclonal antibodies recognizing both
proMMP-9 and active MMP-9. As shown in Figure
1B, similar results were obtained in western blot
analysis , although slightly longer periods were
needed for detection than in the case of gelatin zy-
mography. These results supported the reliability of
gelatin zymography, and therefore we employed it in
the following experiments.
Next, we attempted to characterize the production
of MMP-9 production HCMC. Initially, we examined
the effect of APMA, an MMP activator , on active
MMP-9 production. After 48 hours of incubation with
PMA at a concentration of 10 nM, the supernatant
was collected and further incubated with 1 mM
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Fig. 1 MMP production from HCMC. HCMC were sus-
pended in serum-free medium and incubated with 10 nM 
PMA for indicated periods. ProMMP-9 bands, active MMP-9 
bands and proMMP-2 bands were detected in gelatin zymo-
graphy analysis (A). Western blot analysis were performed 
with PMA stimulated HCMC supernatants by using anti-
MMP-9 antibodies (B). Horseradish peroxidase-conjugated 
antibody was used as a secondary antibody. Proteins were 
visualized using the ECL-plus system. Each result is a repre-
sentative of three independent experiments.
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Fig. 2 Efects of agents on the activation and production 
of MMP-9. After incubation of HCMC with PMA (10 nM) for 
48 hours, the supernatant was colected and further incuba-
ted with APMA (1 mM) for indicated periods (A). PMSF (1 
mM), Act.D (1 μg/ml) and CHX (1 μg/ml) were added to 
HCMC 10 minutes before PMA (10 nM) stimulation, and 
then incubated for 48 hours (B). The samples were subjec-
ted to gelatin zymography under nonreducing conditions. 













APMA for 0.5―12 hours . As shown in Figure 2A,
proMMP-9 band diminished gradually dependent on
the period of incubation and only active MMP-9 band
was detected after 12 hours of incubation. We next
examined the effects of PMSF, Act.D and CHX on
MMP-9 production from HCMC. As shown in Figure
2B, when HCMC was treated with 1 mM PMSF, ac-
tive MMP-9 band was not detectable . Some serine
proteinases from mast cells might contribute to the
conversion of MMP-9 (92 KDa band to 82 KDa band)
in the culture media , which can be inhibited by
chemical serine proteinase inhibitor, PMSF. Further-
more, both 1 μgml Act.D and 1 μgml CHX abol-
ished MMP-9 bands completely. These results indi-
cate that MMP-9 is synthesized de novo upon stimula-
tion with PMA.
CHARACTERIZATION OF MMP-9 PRO-
DUCTION PATHWAY
To determine the MMP-9 production pathway, we ex-
amined the effects of protein kinase C (PKC) inhibi-
tors, staurosporine and Bis II, and mitogen-activated
protein kinase kinase (MEK) inhibitors, U0126 and
PD98059. The specificity of Bis II has been confirmed
by Miura et al.,32 and that of U0126 was established
previously by several investigators.23 As shown in
Figure 3, MMP-9 production was completely inhib-
ited by both the PKC inhibitors and MEK inhibitors.
Accordingly , MMP-9 was produced through the
PKC―MEK―ERK pathway．
When we stimulated HCMC through FcεRI, MMP-
9 production was not induced to any extent (data not
shown) . In order to investigate the difference be-
tween PMA-induced stimulation and FcεRI-mediated
stimulation, we examined the ERK activation through
these stimulation methods . As shown in Figure 4,
PMA-induced activation of ERK was stronger and
longer lasting compared to FcεRI-mediated activa-
tion. This difference, therefore , may be critical re-
gardless of whether MMP-9 was produced or not．
We compared the production of MMP-9 and GM-
CSF from HCMC simultaneously stimulated with
PMA and A23187. As shown in Figure 5A, simultane-
ous treatment with A23187 profoundly inhibited the
PMA-induced MMP-9 production. In contrast, when
HCMC were stimulated with PMA and A23187, dra-
matically increased amounts of GM-CSF were pro-
duced(Fig. 5B).
EFFECTS OF GLUCOCORTICOIDS AND
FLAVONOIDS ON MMP-9 PRODUCTION
FROM HCMC
We attempted to identify efficient agents that could
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Fig. 3 Efects of PKC inhibitors (A) and MEK inhibitors (B) on MMP-9 production 
from HCMC. Staurosporine (1―100 nM), Bis I (0.1―10 μM), U0126 (0.03―3 μM) and 
PD98059 (0.3―30 μM) were added to HCMC 10 minutes before PMA (10 nM) stimu-
lation, and then incubated for 48 hours. The samples were then subjected to gelatin 
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Fig. 4 IgE-mediated (A) and PMA-induced (B) ERK activation in 
HCMC. Sensitized HCMC were chalenged with anti-IgE (4 μg/ml) or 
non-sensitized HCMC were stimulated with PMA (10 nM) for the indi-
cated periods. The total celular proteins were analyzed by SDS-PAGE 
and western bloting. Phosphorylation of ERK was detected with 
phospho-specific antibody. Horseradish peroxidase-conjugated anti-
body was used as a secondary antibody. Proteins were visualized us-
ing the ECL-plus system. Each result is a representative of three 
diferent experiments. Spon: spontaneous.




(B) PMA-induced ERKs activation
Spon
Spon
1 3 5 10 15 30 60 120
Incubation (min)
Incubation (min) Incubation (hr)
5 15 30 1 3 6 12 24
ERK2
Allergology International Vol 55, No1, 2006 www.jsaweb.jp 71
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Fig. 5 Combined efect of A23187 and PMA on MMP-9 (A) and GM-CSF (B) production from HCMC. HCMC 
were stimulated simultaneously with the indicated concentrations of PMA and A23187. For the evaluation of MMP-
9, cels were incubated for 48 hours and then gelatin zymography was performed. For the GM-CSF production, 
cels were incubated for 6 hours and GM-CSF in the supernatant was quantified by ELISA. Result in (A) is a rep-
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Fig. 6 Efects of glucocorticoids (A) and flavonoids (B) on MMP-9 production 
from HCMC. Prednisolone (0.1―10 μM), dexamethasone (0.1―10 μM), luteolin 
(3―30 μM), baicalein and quercetin (30 μM) were added to HCMC before PMA (10 
nM) stimulation, and then incubated for 48 hours. The samples were then sub-
jected to gelatin zymography under nonreducing conditions. Each result is a repre-

















regulate MMP-9 production from human mast cells.
As shown in Figure 6A, prednisolone and dexametha-
sone inhibited MMP-9 production in a dose-
dependent manner. Recently, we reported that cer-
tain flavonoids powerfully inhibited FcεRI-mediated
mediator releases in HCMC.33 As shown in Figure 6
B, the flavonoids, luteolin and quercetin, inhibited the
PMA-induced MMP-9 production．
EFFECTS OF MMP INHIBITORS ON MMP-9
ACTIVITY
Recently, many MMP inhibitors including endogene-
ous MMP inhibitors, TIMP-1 and TIMP-2, have been
reported.9 Therefore, we investigated the effects of
these MMP inhibitors on HCMC-derived gelati-
nolytic activity. As shown in Figure 7A, TIMP-1 and
TIMP-2 clearly inhibited the gelatinolytic activity .
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Fig. 7 Efects of TIMPs and MMP inhibitors on MMP-9 activity . HCMC were incubated with PMA (10 nM) for 48 
hours and the supernatant was colected. This supernatant was electrophoresed with gelatin containing gels. The 
gels were incubated for 24 hours with TIMPs (A) or MMP inhibitors (B). TIMP-1, TIMP-2, AG-3340, marimastat, 
CGS27023A, and Ro32-3555 were used in indicated concentrations. EDTA, which chelates calcium and zinc 
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Synthesized MMP inhibitors such as AG-3340, mari-
mastat, CGS27023A and Ro32−3555 also inhibited the
gelatinolytic activity (Fig. 7B). EDTA abolished the
gelatinolytic activity.
PMA-INDUCED MMP-9, MT1-MMP, TIMP-1
AND TIMP-2 mRNA EXPRESSION IN HCMC
To determine whether MMPs and TIMPs in addition
to MMP-9 and MMP-2 are produced or not, we inves-
tigated the mRNA expression 6―96 hours after PMA
stimulation. As shown in Figure 8, the expression of
mRNA for MMP-9 and MT1-MMP was detectable
from 6 hours after stimulation and increased up to 96
hours . On the other hand , TIMP-1 and TIMP-2
mRNAs were detectable even in non-stimulated cells
and the expression was gradually increased by PMA
stimulation during the incubation．
DISCUSSION
In this study using human mast cells , we demon-
strated for the first time that MMP-9 is produced
through the PKC―MEK―ERK pathway, and that this
production can be regulated by several agents, such
as glucocorticoids and flavonoids. Furthermore, we
found that not only MMP-9 but also MT1-MMP ,
TIMP-1 and TIMP-2 mRNAs were expressed after
PMA stimulation．
Recently, the functions of MMP have been recog-
nized, because they are involved in physiologic proc-
esses such as development, angiogenesis and wound
healing, and in pathologic conditions such as tumor
invasion and inflammation.2,8 MMP is also reported
to play a role in the remodeling of airways and fibro-
sis.15-17 As for inflammatory processes, MMP-9 and
MMP-2 have been especially well investigated , be-
cause these enzymes are potentially involved in the
processes of cellular infiltration from circulation to in-
flammatory sites through the endothelial and epithe-
lial basement membranes . 34 Results from in vitro
studies suggest that lymphocytes,4 neutrophils5 and
eosinophils 6,7 pass through the basement mem-
brane by degrading components with their own
MMP-9 and MMP-2. Although there are many re-
ports that suggest that MMP production originates
from these inflammatory cells, there is little investiga-
tion of mast cells. In contrast to other inflammatory
cells, mast cells are located in inflammatory sites, and
after stimulation these cells produce a variety of cy-
tokines (such as TNF-α, MIP-1α and IL-8),35-38 which
induce the migration of inflammatory cells . There-
fore, mast cell-derived MMPs could degrade extracel-
lular matrix around mast cells to allow other inflam-
matory cells easier migration and accumulation．
Fang et al. reported that SCF-induced MMP-9 pro-
duction in dog BR mastocytoma cells . 21 Further-
more, Tanaka et al. reported that MMP-9 production
is inhibited by SCF-induced activation in mouse bone
marrow-derived mast cells.20 In contrast in HCMC,
MMP-9 production is neither induced nor inhibited
by SCF (data not shown). The difference may con-
tribute to the characteristic of these types of mast
cells. Therefore, in order to investigate the roles of
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Fig. 8 MMP mRNA expression in HCMC stimulated with 
PMA. HCMC were stimulated with PMA (10 nM) for 6―96 
hours, and analyzed mRNA expression for MMP-9, MT1-
MMP, TIMP-1 and TIMP-2 by RT-PCR. The results pre-






0 6 12 24 48 72 96
Incubation time (hr)
mast cells in human pathologic conditions , human
mast cells should be employed. Recently, the produc-
tion of MMP-9 from human mast cells has been re-
ported in HMC-1, HCMC and tissue mast cells (lung,
skin and synovial membrane).19 In this report, we
further investigated the MMP-9 production pathway
from HCMC and its regulation in detail．
At first, we confirmed 92 KDa and 82 KDa bands
are associated with MMP-9 by using APMA and
PMSF. An RNA synthesis inhibitor, Act.D, and a pro-
tein synthesis inhibitor , CHX, completely inhibited
the MMP-9 production . The PMA-induced MMP-9
production, therefore, is due to de novo synthesis. Ac-
tually, gelatinolytic activity was not detected at all in
the non-stimulated HCMC supernatant. We next con-
firmed that MMP-9 production is completely inhib-
ited by both PKC inhibitors and MEK inhibitors .
Therefore, it can be concluded that this MMP-9 pro-
duction is induced by the PKC―MEK―ERK pathway.
Furthermore, PMA-induced MMP-9 production was
inhibited by A23187 in a dose-dependent manner. On
the other hand, GM-CSF production was induced by
PMA and A23187 synergistically . Therefore , this
MMP-9 production is regulated in a different way
from cytokine production such as GM-CSF. Further-
more, although A23187 induce GM-CSF production
from HCMC, it is unable induce MMP-9 production
(data not shown). The mechanism of calcium signal-
ing which leads to two separate phenomena (down-
regulation of MMP-9 and up-regulation of GM-CSF)
should be investigated furthermore. We previously
reported that IgE-mediated mediator release such as
leukotrienes from HCMC are induced through both
the PKC and Ca2+ pathways.29 Therefore , MMP-9
production might not be induced in IgE-mediated
stimulation due to the increase of intracellular Ca2+
levels. Another possibility for the explanation of why
IgE-mediated stimulation could not induce MMP-9
production is the difference of ERK pathway activa-
tion. In PMA-stimulated HCMC, ERK activation is de-
tectable even at 24 hours after stimulation, whereas
IgE-mediated ERK activation is not detectable after
60 minutes. Thus, prolonged activation of the ERK
may play a role in MMP-9 production．
The role of MMP derived from eosinophils and
neutrophils is somewhat obvious. These cells seem to
use MMPs to degrade extracellular matrix, and then
migrate to the inflammatory site.5-7 In contrast, mast
cells are settled in tissues and may not always need to
migrate. Here, we suggest two possibilities that ex-
plain why mast cells produce MMPs. It is already re-
ported that a large number of mast cells are observed
in chronic inflammatory sites.39 Therefore, mast cell
MMPs may play some role in the accumulation of
mast cell in chronic inflammatory sites . As already
described , the other possibility is that mast cell-
derived MMPs destruct matrix around the mast cells
in order to facilitate the migration of other inflamma-
tory cells. Based on these viewpoints, the inhibition
of MMPs production from mast cells might be one of
the strategies involved in the inhibition of chronic in-
flammation such as asthma and chronic obstructive
pulmonary disease.40
Possible strategies for inhibiting the degradation of
extracellular matrix by mast cells are as follows: 1) to
inhibit the MMP production from mast cells, 2) to in-
hibit the gelatinolytic activity of mast cell-derived
MMPs, and 3) to inhibit the conversion to active
MMP-9 because proMMP-9 can not degrade extracel-
lular matrix. Glucocorticoids, luteolin and quercetin
inhibited MMP-9 production from HCMC . These
agents are known to be inhibitors of IgE-mediated
mediator release from mast cells , 33,41 and these
agents are also confirmed as inhibitors of MMP-9
production. Furthermore, we confirmed that MMP-9
activity is inhibited by both endogeneous MMP-9 in-
hibitors and synthesized MMP-9 inhibitors. These re-
sults indicate that mast cell-induced gelatinolytic ac-
tivity is controllable by some agents. As for protease
inhibitors such as PMSF, which inhibit the conver-
sion to active MMP-9, there is retention of MMP-9 as
a latent form．
The balance between MMPs and TIMPs is impor-
tant for the balance of tissue destruction and recon-
struction.10 Although we first detected MMP-9 and
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MMP-2 by gelatin zymography, we further investi-
gated whether other MMPs and TIMPs are produced
from PMA-stimulated HCMC or by RT-PCR. In this
study, we detected TIMP-1, TIMP-2 and MT1-MMP
mRNA expression. TIMP-1 and TIMP-2 mRNAs were
detected also in unstimulated cells, whereas MMP-9
mRNA was not detected under the same conditions.
Therefore, constitutive expression of TIMPs in tissue
resident mast cells may be important for homeosta-
sis . Because mast cells contain the proteolytic en-
zymes tryptase and chymase, it follows that these en-
zymes easily activate proMMP-9 to active form.21 Ac-
cordingly, the expression of TIMPs may regulate the
activation of endogeneous proMMP-9 by the mast
cell enzymes. From this data, non-activated mast cells
might participate in extracellular matrix turnover in
the process of physiological tissue remodeling espe-
cially for tissue reconstruction . Additionally , the
mRNA expression of MT1-MMP is noticeable , be-
cause this membrane type enzyme activates
proMMP-2 more potently than active MMP-3. 24,25
We failed to detect MMP-3 production by HCMC in
western blotting analysis (data not shown), although
the detection of MT1-MMP revealed the possibility
that mast cells can activate mast cell-derived MMP-2
by their surface-expressed MT1-MMP. This must be
a reasonable scenario for the activation of mast cell-
derived MMP-2．
In summary, this report presents the MMP-9 pro-
duction pathway in human mast cells and the regula-
tion of MMP-9 production. Importantly, human mast
cells produce not only MMP-9, MMP-2 and MT1-
MMP but also TIMP-1 and TIMP-2. The balance be-
tween MMPs and TIMPs derived from mast cells
may control the pathogenesis of chronic inflamma-
tion．
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